More than 21,000 bottles of a widely used blood pressure medicine have been recalled across the United States because the tablets may contain more of one active ingredient than they are supposed to, according to a Food and Drug Administration enforcement listing highlighted in new reports this week. The recall covers 21,620 bottles of Viatris Inc. telmisartan and amlodipine tablets, a combination pill taken once a day by people whose blood pressure is not controlled by a single medicine alone.
The important message for patients is a careful one, and it runs through every part of this story: check your bottle, call your pharmacist or doctor if it matches, and do not stop taking a blood pressure medicine suddenly without medical advice. Stopping abruptly can itself be dangerous, and the FDA has put this recall in its lowest-risk category, meaning it judges that use of the product is not likely to cause adverse health consequences.
The recall first appeared in the FDA enforcement system after Viatris, the company behind the generic medicine, voluntarily initiated it on October 1, 2026. Reports by the USA Today network on October 26 and 27 brought the listing to wider attention, and it has since been picked up by health news outlets summarising the FDA report. No other strengths, no other bottle sizes and no other companies are named in this listing: it is specific to the 40 mg telmisartan and 5 mg amlodipine combination, in 30-count bottles, in the five lots listed above.
Superpotency is a quality-control term, not a description of a different drug. It means that, in the lots concerned, the amount of telmisartan in a tablet may be above the specification the product is supposed to meet. Telmisartan is the angiotensin II receptor blocker in the combination: it relaxes blood vessels by blocking a substance that makes them tighten. Amlodipine, the calcium channel blocker in the same tablet, also relaxes and widens blood vessels. Together they lower blood pressure more effectively than either drug alone for many patients, which is why the combination exists in a single pill.
The FDA listing does not state how far above specification any tablet might be, and it does not report any injuries linked to these lots in the summaries reviewed for this article. That absence of detail is itself part of the story. Class III is the FDA's lowest-risk recall class, used when the agency judges that exposure to the product is not likely to cause adverse health consequences. It is a very different category from the Class II recalls that have dominated recent food and drug headlines, where temporary or medically reversible harm is considered possible, and from Class I recalls, where serious harm or death is a reasonable probability.
Even so, the prescribing information for telmisartan, held by the National Library of Medicine, warns that an overdose could cause low blood pressure, known as hypotension, dizziness or a rapid heart rate, known as tachycardia. Those are the symptoms patients and pharmacists are watching for, and they are the reason the advice is to seek advice rather than to ignore the recall or to panic about it. A tablet that is modestly stronger than labelled is not the same as a tablet containing the wrong drug, and the FDA's classification reflects that distinction.
High blood pressure is one of the most common long-term conditions in the United States, and combination pills like this one are a routine part of treatment. Doctors often move a patient to a combination when a single medicine does not bring readings down far enough, because two drugs working in different ways can control pressure at lower doses of each than either drug alone at a high dose. Telmisartan belongs to the same family as losartan and valsartan, drugs many patients will recognise, while amlodipine is one of the most widely prescribed blood pressure medicines in the country.
Generic medicines are held to the same potency specifications as brand-name medicines. Manufacturers test batches against those specifications, and when a batch fails, or may fail, the remedy is a recall to the consumer level: pharmacies and distributors are told to return the stock, and patients are told to check what they hold. That is what has happened here, on a comparatively small scale. At 21,620 bottles of 30 tablets each, the recall covers about 648,600 tablets, a fraction of the tens of millions of blood pressure prescriptions filled in the United States every year.
The recall also arrives in a busy month for FDA enforcement reports. The same October listings that carried this recall also included a subpotent thyroid medicine, levothyroxine, and a labelling mix-up involving an epilepsy medicine, perampanel, in which a bottle labelled 6 mg was found to contain a 10 mg tablet. Those are separate products, separate companies and separate problems, but together they illustrate why the enforcement report is read so closely by pharmacists: small manufacturing and labelling errors in common medicines can reach a very large number of people before they are caught.
There is also a longer history that makes patients understandably nervous about blood pressure recalls. In 2018 and 2019, valsartan and related medicines were recalled in large numbers after a probable carcinogen, an impurity called NDEA, was found in the active ingredient made by one manufacturer. That was a different problem, a contaminant rather than a potency issue, and it involved a different drug. It is mentioned here only because patients searching for blood pressure recalls will meet it, and it should not be confused with this Viatris recall, which is about telmisartan content exceeding a specification, not about a carcinogenic impurity.
Checking takes less than a minute, and it is the single most useful thing a reader of this article can do. First, find the bottle for telmisartan and amlodipine tablets, 40 mg/5 mg. The label should show the strength and the manufacturer. Then look for the lot number and the expiry date, usually printed on the bottle or on the pharmacy label, and compare them with the five affected lots: 3228113, 3228114 and 3228115, all expiring October 31, 2026, and 3228120 and 3228121, both expiring November 30, 2026. The National Drug Code for the product is 0378-1075-93.
If your bottle does not match any of those lots, this recall does not apply to it, and you should carry on taking it exactly as prescribed. If it does match, do not throw it away in a panic and do not stop taking it. Call your pharmacy first. Pharmacists deal with recalls every week, they can confirm whether your bottle is affected, they can arrange a replacement, and they can tell you whether you need to speak to your prescriber urgently. If your pharmacy is closed, keep taking the medicine as prescribed until you can reach a pharmacist or doctor, unless you develop symptoms that need urgent care, in which case seek medical help at once.
It is worth noting that three of the affected lots expire on October 31, 2026, four days after this article is published, and the other two expire on November 30. That does not make the recall unimportant: a patient may still hold a bottle from an October lot, and pharmacies may still hold stock. But it does mean that, for many patients, the affected supply is already near the end of its shelf life, which is one more reason the FDA's risk assessment is low.
Patients who use a pill organiser should also check. If tablets have already been moved out of the original bottle, the lot number may be lost, and the pharmacy that dispensed them can usually trace the lot from its dispensing records. That is another reason to call the pharmacy rather than to guess.
The FDA's own language frames the risk plainly. A Class III recall, in the agency's definition, is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. That sentence, quoted in the health reports covering this recall, is the most important single line in the story, because it separates a recall that demands a check from a recall that demands alarm.
The USA Today network reports carry the practical advice in the same terms: people with the medication should not stop immediately taking it, as potential withdrawals may be more harmful, and should reach out to a doctor or pharmacist with questions or concerns. That advice reflects a well-known problem in blood pressure treatment. Blood pressure that rebounds after sudden withdrawal can rise sharply, and for a patient with heart disease or a previous stroke, that rebound can be more dangerous than a short period on a slightly stronger tablet.
Health outlets summarising the FDA report have also repeated the National Library of Medicine warning about overdose symptoms: low blood pressure, dizziness and a rapid heart rate. Those are symptoms to act on, not symptoms to wait out. Anyone who feels faint, unusually dizzy or aware of a racing heartbeat after taking this medicine should seek medical advice promptly, whether or not their bottle is on the affected list, because those symptoms always deserve attention in a person being treated for high blood pressure.
No statement from Viatris beyond the recall initiation itself was included in the reports reviewed for this article, and no patient injuries have been reported in those summaries. If the company or the FDA publishes further detail, including the size of the potency deviation, this article's advice would not change: check the lot, call the pharmacy, and do not stop suddenly.
This recall matters for a reason that has little to do with its size. Blood pressure medicines are taken every day, for years, by people who often feel perfectly well. A recall notice therefore lands differently from a food recall: the patient cannot see the problem, cannot taste it, and may be tempted either to ignore it or to stop the drug in fear. Both responses are wrong, and the space between them, check and ask, is where safe medicine use actually happens.
It also matters because it is a test of how recall information travels. The FDA enforcement report is a technical document, written for pharmacists and manufacturers. Most patients meet it only through news reports, and those reports have to translate lot numbers, drug codes and recall classes into a decision a person can make at a kitchen table. That translation is the job of this article: five lots, two expiry dates, one product code, one phone call to a pharmacy, and one rule, do not stop suddenly.
Finally, it matters because high blood pressure itself is a silent risk. It damages arteries, heart, kidneys and brain without symptoms, and the benefit of keeping it controlled dwarfs the low risk the FDA has assigned to this recall. A patient who stops a blood pressure medicine because of a recall notice, and then has a stroke, has been harmed not by the recall but by the response to it. That is why every recall notice for a long-term medicine carries the same warning, and why it is repeated here.
For pharmacies and distributors, the next step is procedural: check stock against the five lots, quarantine any affected bottles, and return them through the normal recall channel. For patients, the next step is personal: check the bottle, call the pharmacy if it matches, and arrange a replacement before the current supply runs out. The recall itself will remain on the FDA enforcement record, and the agency may publish a closing notice once the return is complete.
Patients who are switched to a replacement should expect the same medicine, from a different lot or a different manufacturer, at the same strength, unless their prescriber decides otherwise. A change of manufacturer for a generic medicine is routine, and pharmacists can explain any difference in tablet appearance. Blood pressure should be checked as usual after a switch, as it should be after any change in supply.
Readers who want to check other recent recalls can find related coverage below, including the plant-based butter recall in ten states and the nationwide toothpaste recall. Those are different products and different risks, but the habit is the same: check the lot, follow the return advice, and ask a pharmacist when in doubt.
Related coverage: Miyoko's butter recall: plant-based spread pulled in 10 states over E. coli fears; Toothpaste recall: 4.3 million tubes pulled nationwide, check your cabinet now; Darwin's cat food salmonella alert: FDA warns two lots after cat hospitalised.
Viatris telmisartan and amlodipine tablets, 40 mg/5 mg, in 30-count bottles, product code NDC 0378-1075-93. Only five lots are affected: 3228113, 3228114 and 3228115, expiring October 31, 2026, and 3228120 and 3228121, expiring November 30, 2026.
The FDA listing gives the reason as superpotency: the telmisartan content in the affected lots may exceed the established potency specifications. The listing does not say by how much, and it is classified as a Class III recall, the FDA's lowest-risk class.
No, not on your own. Contact your pharmacist or prescriber first and arrange a replacement. Stopping a blood pressure medicine suddenly can cause blood pressure to rebound, which can be more harmful than a short period on a slightly stronger tablet. Seek urgent medical help if you feel faint, dizzy or notice a racing heartbeat.
Call the pharmacy that dispensed them. Pharmacies can usually trace the lot from dispensing records, and they can advise whether a replacement is needed even when the original bottle is gone.
No. The listing names only this Viatris combination product, this strength, this bottle size and these five lots. Other brands, other strengths and other manufacturers are not covered by this recall.
Sources: FDA enforcement report via MedShadow, USA Today network (Courier-Post, October 26, and Bucks County Courier Times, October 27), The Healthy, New Telegraph and Epoch Times summaries, October 26-27, 2026. This article is for information only and is not medical advice; speak to your pharmacist or prescriber about your own medicine.
Leave a Comment
| Today's Date:
